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treatment plans on which we delineated the anal-sphincter region 
(ASR) and the rectum following the outer border (Figure). We 
delineated the anal-sphincter region extending from the end of the 
rectal ampulla to the anus. The rectum was delineated from the 
recto-sigmoid junction to the end of the rectal ampulla. Fecal leakage 
was assessed in the questionnaire by the question 'Have you had fecal 
leakage while awake, the previous six months?'. The responses were 
dichotomized at a level of symptom occurrence at least once a month. 
 
 Results: Prostate-cancer survivors who reported faecal leakage at 
least once a month had received an average mean dose to the rectum 
of 47.8 Gy compared to 44.0 Gy for those who reported faecal leakage 
less than once a month (two-sided t test p=0.009). When stratifying 
the mean absorbed dose to the rectum in 5 Gy-bins we found a 
statistically significantly higher occurrence of faecal leakage 
compared to population-based controls from 35 Gy and above. Men 
who had received a mean absorbed dose of ≥40 Gy to the anal-
sphincter region (IJROBP 2012;84:e131) and ≥35 Gy to the rectum had 
the highest prevalence ratio 4.6 (95% CI 2.2–9.5) of faecal leakage 
compared to controls (Table). 
 
  
Conclusions: Our results suggest that the combination of dose to the 
anal-sphincter region and dose to the rectum contributes to the 
excess risk of long-term faecal leakage after radiation therapy for 
prostate cancer. These findings indicate that future prediction models 
for this symptom may need to consider both these organs-at-risk.  
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Purpose/Objective: Since the objective of conservative treatment, in 
addition to local control and survival, is the aesthetic result, the 
acute toxicity and cosmetic outcome evaluation is essential. Here we 
present the results of the first 256 breast cancer pts treated with 
HPRT scheme. 
Materials and Methods: Clinical records of 294 breast cancer pts 
receiving postoperative HPRT after conservative surgery pts had been 
evaluated. Age: Mean 57.26 years (range 30-80). Tumor location: 
54.08% (158) of the pts on the right breast and 45.92% (136) on the 
left. Surgical treatment: Lumpectomy+sentinel node technique (181 
pts, 61.56%), quandrantectomy+axillary dissection (60 pts, 20.40%), 
and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI 
(94.89%). Tumor size: 1.39 cm. (range 0.4-5.8). Histological grade: GI 
29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) 
with positive margins. Hormone receptors: (-) in 6.46%. HER-2: (-) in 
11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: 
Mean 12.5 (range 1-24). Positive 1.02 (range 0-2). Stage: I 70.06%, II 
27.55%, and III 2.39%. RTP schedule: Breast: 40.5 Gy in 15 fractions of 
2.7 Gy. Boost: 103 pts (35.03%) received no boost, 176 (59.86%) 
received 10 Gy/5fr and 15 (5.11%) received 14 Gy/7fr. Adjuvant 
chemotherapy: 52.38%. Hormone therapy: 58.87%. Follow-up 
schedule: Weekly based during RTP, 1 month after the end of RTP 
and, later, every three months. 
Results: 77 pts (26.19%) developed radiodermatitis. Of these, 88.31% 
Grade I and 11.69% Grade II. The mean dose at which radiodermatitis 
appeared was 34.92 Gy (range 13.5-46.5). After 12 months of follow-
up, only 17 pts (5.78%) had a slight residual hyperpigmentation in the 
treated area. 
Conclusions: With careful planning, acute toxicity and cosmetic 
outcome of HPRT are perfectly comparable to that obtained with 
conventional fractionation. Thus, in addition, this treatment scheme 
reduces total time of treatment and, therefore, a decrease in the 
waiting list is achieved. 
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Purpose/Objective: In breast cancer pts it’s crucial, because of its 
high survival, to study the possibilities of developing a radiation-
induced cancer. In its development are implicated low range radiation 
doses (up to 20 to 30 Gy, depending on the tumor type) received by 
the healthy tissue, except for second sarcoma, induced at higher 
doses. The dose over the entire breast is 50 Gy, and therefore this 
dose is outside the above range. The purpose of this study is to 
analyze the effects of boost performed, whose value is between 10 
and 16 Gy [included within the dosage range previously mentioned as 
potential inducer of second cancers in areas as homolateral (HL) and 
contralateral lung (CL) and breast (CB)] and find out if there is any 
difference if its delivered by PH or E and, therefore, one technique is 
more cancer inductive than the other. We present the results of the 
first five pts. 
Materials and Methods: 5 consecutive breast cancer pts, treated with 
conservative intend, undergoing radiotherapy, were enrolled. The 
Eclipse (Varian) version 10.0 planning system was used for treatment 
planning and dose-volume histograms (DVH) analysis. Statistical 
analysis of data was performed by MATLAB software. For each pt, two 
different boost planning options were calculated; one by PH and 
another by E. DVH of each were analyzed and determined: a) Volume 
(cm3) of HL and CL receiving a dose between 5 and 20 Gy (V5-20 Gy). 
b) Volume (cm3) of CB receiving a dose between 5 and 10 Gy (V5-10 
Gy). c) Volume (cm3) of esophagus receiving a dose between 10 and 20 
Gy (V10-20 Gy). These cancer induction dose ranges had been 
reported by Schneider et al in 2011. Also, the mean integral dose in 
the treated breast (MIDB) and the mean integral dose received in the 
whole simulation volume (MIDWSV) were determined for each patient. 
A Wilcoxon-Mann Whitney test was performed for each organ. 
Results: The Wilcoxon-Mann Whitney test was performed for HL, MIDB 
and MIDWSV because, in the other organs we observed that the 
volumes receiving doses considered limiting were null. The test 
showed that the null hypothesis was true (median equal for both data 
samples, with a significance level of 5%) for HL, but false for MIDB and 
MIDWSV. Therefore, in the group of patients, no significant 
differences were found in HL between both boost treatment 
modalities (PH or E), but they were found for MIDB (increased for E) 
and for MIDWSV (increased for PH). 
Conclusions: There is a significant difference between E or PH boost 
regarding low doses in distant organs. Not differences were found 
regarding lung doses for both techniques. E boost possibly is more 
related to higher probability of homolateral induced sarcoma. Integral 
dose is also higher in PH boost. Integral dose has been linked to 
general cancer induction. This low dose distribution might be used as 
